GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies

The combined power of the Trianni and GigaGen technologies will produce an unprecedented pipeline of fully-human antibodies

GigaGen Inc., a biopharmaceutical company with patented technology for discovery of antibody therapeutics from millions-diverse immune repertoires, today announced a strategic partnership with Trianni, Inc., a biotechnology company that has developed novel mouse strains genetically engineered to express human antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through The Trianni Mouse platform.

“The combined power of the Trianni and GigaGen technologies will produce an unprecedented…

Read the complete version from the Source…

Back to Top